Unique ID issued by UMIN | UMIN000022688 |
---|---|
Receipt number | R000026149 |
Scientific Title | A pilot study of reduced intensity conditioning allogeneic stem cell transplantation with dose-adjusted busulfan for chronic granulomatous disease |
Date of disclosure of the study information | 2016/06/13 |
Last modified on | 2021/06/14 12:05:52 |
A pilot study of reduced intensity conditioning allogeneic stem cell transplantation with dose-adjusted busulfan for chronic granulomatous disease
A pilot study of RIC-SCT for CGD
A pilot study of reduced intensity conditioning allogeneic stem cell transplantation with dose-adjusted busulfan for chronic granulomatous disease
A pilot study of RIC-SCT for CGD
Japan |
Chronic granulomatous disease
Hematology and clinical oncology | Pediatrics |
Others
NO
To assess the efficacy and safety of reduced intensity conditioning stem cell transplantation with dose-adjusted busulfan for chronic granulomatous disease.
Safety,Efficacy
Event free survival at day 100
1. Engraftment probability at day 30
2. Mortality at day 100
3. Incidence of infectious disease at week 8
4. Reconstruction of immune status
5. Time from transplantation to onset of acute GVHD
6. Reconstruction of neutrophil function
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Conditioning regimen with targeted-busulfan and fludarabin
Total body irradiation (3Gy) at day -1
Stem cell transplantation at day 0
Not applicable |
25 | years-old | > |
Male and Female
1) Diagnosed as chronic granulomatous disease
2) Planned to have stem cell transplantation
3) Donor for transplantation is one of the follows;
a. HLA 5/6 (A, B, DR) or more matched related donor
b. HLA 5/6 (A, B, DR) or more matched unrelated donor
4) Age at transplantation <25 years
5) ECOG Performance status: 0-2
6) Sufficient organ function, as follows;
a. T-Bil <= 1.5 mg/dl
b. Serum creatinine <= 0.8 mg/dl (age <5y), <= 1.2 mg/dl (age 5-9y), <= 1.5 mg/dl (10y or older)
c. Ejection fraction 45% or better, and QTfc <0.45 sec
7) Obtained informed consent from a guardian of the patient
1. Intracranial hemorrhage
2. Severe psychological disorders
3. Pregnant or suspected pregnancy
4. Not eligible for this study at the discretion of the investigator.
9
1st name | Motohiro |
Middle name | |
Last name | Kato |
National Center for Child Health and Development
Children's Cancer Center
157-8535
2-10-1, Okura, Setagaya, Tokyo
03-3416-1811
kato-mt@ncchd.go.jp
1st name | Motohiro |
Middle name | |
Last name | Kato |
National Center for Child Health and Development
Children's Cancer Center
157-8535
2-10-1, Okura, Setagaya, Tokyo
03-3416-1811
kato-mt@ncchd.go.jp
National Center for Child Health and Development
National Center for Child Health and Development
Other
National Center for Child Health and Development
2-10-1, Okura, Setagaya-ku, Tokyo
03-3416-0181
rinri@ncchd.go.jp
NO
2016 | Year | 06 | Month | 13 | Day |
Unpublished
Completed
2016 | Year | 05 | Month | 26 | Day |
2016 | Year | 05 | Month | 26 | Day |
2016 | Year | 06 | Month | 10 | Day |
2018 | Year | 06 | Month | 28 | Day |
2018 | Year | 06 | Month | 28 | Day |
2018 | Year | 06 | Month | 30 | Day |
2018 | Year | 07 | Month | 27 | Day |
2016 | Year | 06 | Month | 10 | Day |
2021 | Year | 06 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026149